Allergy Therapeutics PLC Director/PDMR Shareholding (4794T)

TIDMAGY

RNS Number : 4794T

Allergy Therapeutics PLC

12 October 2017

12 October 2017

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Director/PDMR Shareholding

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that, on 11 October 2017, Tunde Otulana, Non-Executive Director of the Company, purchased 25,000 ordinary shares of 0.10p in the Company ("Ordinary Shares") at a price of $0.5066 per Ordinary Share (equivalent to 38.41p per Ordinary Share)*. Mr Otulana's total beneficial holding now amounts to 25,000 Ordinary Shares, which represents 0.004% of the issued share capital of the Company to which voting rights are attached.

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ----------------------------------------------------- 
 a)   Name               Babatunde (Tunde) Otulana 
---  -----------------  ---------------------------------- 
 2    Reason for the notification 
       Acquisition of shares 
---  ----------------------------------------------------- 
 a)   Position/status    Non-Executive Director 
---  -----------------  ---------------------------------- 
 b)   Initial            Initial notification 
       notification 
       /Amendment 
---  -----------------  ---------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ----------------------------------------------------- 
 a)   Name               ALLERGY THERAPEUTICS PLC 
---  -----------------  ---------------------------------- 
 b)   LEI 
---  -----------------  ---------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ----------------------------------------------------- 
 a)   Description        Ordinary Shares of GBP0.0001 each 
       of the 
       financial 
       instrument, 
       type of 
       instrument 
 
       Identification 
       code 
---  -----------------  ---------------------------------- 
 b)   Nature             Purchase of Ordinary Shares 
       of the 
       transaction 
---  -----------------  ---------------------------------- 
 c)   Price(s)             Price(s)         Volume(s) 
       and volume(s)       ---------------  ---------- 
                            $0.5066 
                             per Ordinary 
                             share           25,000 
                           ---------------  ---------- 
---  -----------------  ---------------------------------- 
 d)   Aggregated 
       information 
 
 
       - Aggregated 
       volume              25,000 ordinary shares 
 
 
       - Price             $12,665.00 
---  -----------------  ---------------------------------- 
 e)   Date of            11 October 2017 
       the transaction 
---  -----------------  ---------------------------------- 
 f)   Place of           United States 
       the transaction 
---  -----------------  ---------------------------------- 
 

This announcement contains insider information for the purposes of Article 7 of Regulatory (EU) No596/2014.

*calculated at a rate of GBP GBP1.00 to USD $1.3189, as at midday (BST) 11 October 2017

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan / Philippa Gardner

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBXBDGBUBBGRD

(END) Dow Jones Newswires

October 12, 2017 09:55 ET (13:55 GMT)